Amendment Disclosure: GI Innovation Adds FDA Approval Details for GI-102 and Pasritamig Combo Prostate Cancer Trial
GI Innovation amended its previously disclosed clinical trial plan approval for the combination of GI-102 and pasritamig in metastatic castration-resistant prostate cancer, adding FDA approval details.
The amendment revises the FDA approval date from April 18, 2026 to June 26, 2026, changes the IND number from 164293 to 182766, and sets the confirmed date as June 30, 2026.
The Phase 1b/2 trial is conducted under a collaboration agreement with Janssen in South Korea and the US, targeting up to 107 patients with an expected completion by April 2029. Statistically, the probability of final drug approval is about 10%, highlighting the high risk of failure.
[AI Summary]This amendment is an administrative correction officially reflecting the FDA approval date and number. It involves no new capital raising or change in capital structure, thus neutral for the stock price. However, as an early-stage trial, investors should remain cautious about potential volatility from future results.
KOSDAQ Filing Information
[Correction of Description] Major Management Matters Related to Investment Decision (Decision on Clinical Trial Plan Approval Application, etc.) (Approval of Phase 1b/2 Clinical Trial Plan to Evaluate Anticancer Activity, Safety, and Tolerability of GI102 in Combination with Pasritamig in Patients with Metastatic Castration-Resistant Prostate Cancer)